Full-Life Technologies, a China-based, fully integrated global radiopharmaceutical company, announced on Monday that it has named Steffen Heeger, MD, PhD as its new chief medical officer (CMO) and Fa Liu, PhD as its new chief scientific officer (CSO).

Dr Heeger has served in senior oncology clinical development positions at both large and emerging companies for over 15 years. He started his career at Merck KGaA where he played a key role over nine years in the development of Erbitux. He has served as vice president and head of Clinical Development at Morphosys. He has held the position of chief medical officer at Selvita, SA and CMO at Pega-One.

Dr Liu is a peptide chemist and has served as head of Chemistry at Novo Nordisk. He has co-founded and served as CEO of Focus-X. He has held the position of Hhad of Chemistry at Novo Nordisk Research Centers in the US and Head of Chemistry at Calibrium LLC. He started his career at Eli Lilly, where he headed various peptide lead optimisation efforts and established the modern insulin chemistries. He has served at National Cancer Institute focusing on cancer drug discovery.